Orexigen announces strategic acquisition of all U.S. rights to Contrave®, the market leading branded anti-obesity prescription medicine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
RBC Capital Sees Tough Road Ahead Following Orexigen Therapeutics' (OREX) Takeda Partnership Termination; Cuts PT to $0.60
March 16, 2016 9:46 AM EDTRBC Capital maintained a Sector Perform rating on Orexigen Therapeutics (NASDAQ: OREX), and cut the price target to $0.60 (from $1.00), following the company's announced termination of the Takeda partnership. OREX plans to commercialize Contrave in the US by building its own commercial infrastructure. As... More
Leerink Lowers Leerink (OREX) PT to $1 on Move to Acquire Contrave Rights from Takeda
March 16, 2016 7:56 AM EDTLeerink Partners analyst, Paul Matteis, noted that Orexigen Therapeutics (NASDAQ: OREX) acquired the Contrave rights from Takeda and lowered his price target to $1 (from $2) on shares as a result. The firm maintained its Market Perform rating.
Yesterday morning OREX announced that it has entered into a deal with Takeda where it will acquire US commercial rights to Contrave; concurrently, OREX also... More
Piper Jaffray Downgrades Orexigen Therapeutics (OREX) to Neutral
March 16, 2016 6:35 AM EDTPiper Jaffray downgraded Orexigen Therapeutics (NASDAQ: OREX) from Overweight to Neutral with a price target of $2.00 (from $5.00).
Analyst Charles Duncan commented, "Yesterday Orexigen announced it plans to terminate its commercial partnership with Takeda for Contrave in the US market. We believe this... More
JMP Securities Downgrades Orexigen Therapeutics (OREX) to Market Perform
March 16, 2016 6:34 AM EDTJMP Securities downgraded Orexigen Therapeutics (NASDAQ: OREX) from Market Outperform to Market Perform and removed its price target (prior $2.00).
For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $0.64 yesterday.
... MoreOrexigen Therapeutics (OREX) Enters Mysimba Commercialization Agreement with Valeant (VRX)
March 15, 2016 7:03 AM EDTOrexigen Therapeutics, Inc. (Nasdaq: OREX) announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. The distribution agreement between Valeant Holdings Ireland and Orexigen's wholly owned subsidiary, Orexigen Therapeutics Ireland Ltd., includes 12 countries where Mysimba has been approved for marketing in the European Union (EU): Greece, Slovenia, Slovakia, Czech Republic, Hungary, Croatia, Lithuania, Estonia, Poland, Latvia, Bulgaria, and Romania. The agreement also extends to several non-EU countries where Valeant will apply for marketing authorization: Serbia, Bosnia and Herzegovina, Albania, Macedonia, Montenegro,... More
